REDWOOD CITY, Calif., May 13, 2016 /PRNewswire/ -- Guardant Health®, the leader in comprehensive liquid biopsies, announced it will present data on the somatic genomic landscape found in more than 15,000 clinical Guardant360® samples at the annual meeting of the American Society of Clinical Oncology (ASCO) June 3-7 in Chicago.
The presentation is one of 15 abstracts highlighting the performance and clinical utility of Guardant Health's digital sequencing technology accepted for oral and poster presentations at ASCO this year. Collaborators from UC Davis Cancer Center, The University of Texas MD Anderson Cancer Center, Thomas Jefferson University, University of California, San Francisco, UC San Diego Moore's Cancer Center, University of Alabama at Birmingham Comprehensive Cancer Center, the Avera Cancer Institute, The West Clinic, Samsung Medical Center and NovellusDx will present their findings about Guardant360 as applied to a variety of cancer types and applications.
Guardant360, the first and most validated comprehensive liquid biopsy, has been used by more than 2,000 oncologists to help match patients with advanced cancer to targeted therapies. Guardant Health's digital sequencing platform allows for comprehensive analysis of all major classes of somatic tumor alterations from a simple blood draw, with near-perfect specificity and high sensitivity. Guardant360 can detect alterations in fragments of circulating tumor DNA at levels as low as 0.1% mutant allele fractions.
The schedule of presentations:
Podium presentation
Date and Time: Tuesday, June 7 from 8:12-8:24 am
Title: Somatic genomic landscape of over 15,000 patients with advanced-stage cancer from clinical next-generation sequencing analysis of circulating tumor DNA
Abstract: 11501
Location: Room S100a, McCormick Place
Presenter: Philip C. Mack, PhD, UC Davis Cancer Center
First author: Oliver Zill, PhD, Guardant Health
Poster discussion
Date and Time: Saturday, June 4 from 1-4:30 pm
Title: Characterization of cell-free circulating tumor DNA in patients with brain metastases
Abstract: 2023
Location: Hall A
Poster Board Number: 212
Presenter: Nadia Faiq, BA, UC San Diego Moores Cancer Center
Collaborators: UC San Diego Moores Cancer Center
Poster presentations
Date and Time: Saturday, June 4 from 8-11:30 am
Title: Significant systemic and CNS activity of RET inhibitor vandetanib combined with mTOR inhibitor everolimus in patients with advanced NSCLC with RET fusion
Abstract: 9069
Location: Hall A
Poster Board Number: 392
Presenter: Tina Cascone, MD, PhD, The University of Texas MD Anderson Cancer Center
Collaborators: MD Anderson Cancer Center
Date and Time: Saturday, June 4 from 8-11:30 am
Title: Circulating tumor DNA as a non-invasive tool to identify patients at risk for recurrence after chemoradiotherapy in stage III non-small cell lung cancer
Abstract: 8553
Location: Hall A
Poster Board Number: 181
Presenter: Steven H. Lin, MD, PhD, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center
Collaborators: MD Anderson Cancer Center
Date and Time: Saturday, June 4 from 1-4:30 pm
Title: Clinical genomic testing of anaplastic thyroid carcinoma (ATC) and need for integration into future prospective clinical trials
Abstract: 6085
Location: Hall A
Poster Board Number: 407
Presenter: Vlad Sandulache, MD, Department of Head and Neck Surgery, University of Texas MD Anderson Cancer Center
Collaborators: MD Anderson Cancer Center
Date and Time: Saturday, June 4 from 1-4:30 pm
Title: Circulating cell free DNA to predict recurrence in uveal melanoma
Abstract: 9569
Location: Hall A
Poster Board Number: 174
Presenter: Ryan Michael Weight, DO, Thomas Jefferson University Hospital
Collaborators: Thomas Jefferson University
Date and Time: Saturday, June 4 from 1-4:30 pm
Title: Circulating cell-free DNA profiling of patients with advanced urothelial carcinoma of the bladder.
Abstract: 4528
Location: Hall A
Poster Board Number: 151
Presenter: Rebecca Nagy, MS LGC, Guardant Health
Date and Time: Sunday, June 5 from 8-11:30 am
Title: Role of genomic instability in immunotherapy with checkpoint inhibitors
Abstract: 3052
Location: Hall A
Poster Board Number: 374
Presenter: George Yaghmour, MD, West Clinic
Collaborators: West Clinic
Date and Time: Monday, June 6 from 1-4:30 pm
Title: Prospective evaluation of circulating cell-free DNA sequencing in patients with metstatic renal cell carcinoma treated with pazopanib plus abexinostat
Abstract: 4551
Location: Hall A
Poster Board Number: 173
Presenter: Jim Leng, University of California, San Francisco
Collaborators: University of California, San Francisco
Date and Time: Monday, June 6 from 1-4:30 pm
Title: Investigating the utility of comprehensive genomic profiling for patients with newly diagnosed breast cancer
Abstract: TPS11617
Location: Hall A
Poster Board Number: 312b
Presenter: Casey B. Williams, Pharm.D., BCOP, Avera Cancer Institute
Collaborators: Avera Cancer Institute
Date and Time: Monday, June 6 from 1-4:30 pm
Title: Profiling of circulating tumor (ct)-DNA for potentially actionable targets in prostate cancer (PCa)
Abstract: 5035
Location: Hall A
Poster Board Number: 292
Presenter: Guru Sonpavde, MD, University of Alabama at Birmingham Comprehensive Cancer Center
Collaborators: University of Alabama at Birmingham Comprehensive Cancer Center
Date and Time: Monday, June 6 from 1-4:30 pm
Title: Detection, frequency and actionability of recurrent copy number gains detected by non-invasive liquid biopsy of 3,942 lung and breast cancer samples
Abstract: 11541
Location: Hall A
Poster Board Number: 238
Presenters: Diana Abdueva, PhD, Guardant Health
Date and Time: Monday, June 6 from 1-4:30 pm
Title: Early, molecular detection of cancer utilizing circulating cell-free DNA assay with ultra high accuracy and sensitivity
Abstract: 11540
Location: Hall A
Poster Board Number: 237
Presenter: Stefanie Mortimer, PhD, Guardant Health
Date and Time: Monday, June 6 from 1-4:30 pm
Title: Functional characterization of VUS mutations found in patients' cell-free circulating tumor DNA (ctDNA) using Precision Cancer Analysis System (PCAS)
Abstract: 11576
Location: Hall A
Poster Board Number: 237
Presenter: Gabi Tarcic, PhD, NovellusDx
Collaborators: NovellusDx
Date and Time: Monday, June 6 from 1-4:30 pm
Title: Cell-free DNA sequencing-guided therapy in a prospective clinical trial: NEXT-2 trial—A feasibility analysis
Abstract: 11534
Location: Hall A
Poster Board Number: 231
Presenter: Jeeyun Lee, MD, PhD, Samsung Medical Center
Collaborators: Samsung Medical Center
Guardant Health is also an exhibitor at the ASCO annual meeting. Company representatives will be available to provide additional information on Guardant Health and Guardant360 at booth #3089.
About Guardant Health
Guardant Health, headquartered in Redwood City, Calif., is focused on developing breakthrough diagnostics that can transform cancer from a silent killer into a manageable disease. Guardant Health was founded in 2012 by a team of serial entrepreneurs with expertise in next-generation sequencing, single-cell genomics and cancer diagnostics. The team is committed to positively and significantly impacting patient health through technology that addresses long-standing unmet needs in oncology.
Logo - http://photos.prnewswire.com/prnh/20140212/SF64352LOGO
SOURCE Guardant Health